Navigation Links
Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
Date:7/8/2009

nilethera.com' target='_new'>http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission on March 12, 2009. Nile is providing this information as of the date of this press release and does not undertake any obligation to update an
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
(Date:7/10/2014)... researchers at the University of Illinois at Urbana-Champaign ... the interplay of spin and heat at the ... spintronic devices for data storage and information processing. ... as spin-angular momentum. In a typical charge current, ... spin current," explained David Cahill, a professor of ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2
... 27 A copy of the Company,s December 31, 2008 ... may be obtained without charge at our website address, ... P. O. Box 14508, St. Louis, Missouri 63178. About ... Science and High Technology ...
... - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today reported ... 30, 2008. All dollar amounts referenced herein are in Canadian ... cash and cash equivalents totaled $8.6 million, compared with $23.5 ... 31, 2008. As of January 31, 2009, our cash balance ...
... option for millions of Americans with debilitating lung ... (NYSE: AZN ) today announced that ... approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for ... in patients with chronic obstructive pulmonary disease (COPD), ...
Cached Biology Technology:Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... La Jolla, CA, October 28, 2010 For Immediate ... Research Institute and the Scripps Translational Science Institute has ... collections of rare genetic variations that reveal whether people ... cancer. In our modern genetic age, the ...
... Ancient gardens are the stuff of legend, from the Garden ... at Tel Aviv University, in collaboration with Heidelberg University in ... of Ramat Rachel near Jerusalem, and are leading the first ... the pre-Hellenistic Levant. According to Prof. Oded ...
... clung to life in the branches of trees hemming ... more than 230,000 coastal residents in Indonesia, India, Thailand ... land change scientist Chandra Giri from the U.S. Geological ... unique trees which make up valuable forest ecosystems ...
Cached Biology News:Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3Paradise lost -- and found 2Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 2Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 3Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 4Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 5
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
... known as smooth muscle cell specific protein, is ... various tissues such as intestine, lung and uterus. ... calponin. SM22 alpha expression has been reported in ... vascular and visceral forms. It is also reported ...
Biology Products: